US FDA’s OPQ Reshapes For More Nimble Approach To Drug Quality Reviews

 
• By Bowman Cox

Reorganization in January expected to leave CDER’s nine-year-old pharmaceutical quality assessment organization more adaptable to public health emergencies, new pharmaceutical technologies and market dynamics, while further blending approaches to new and generic drug reviews.

Organization chart
OPQ removes organizational pain points • Source: Shutterstock

More from US FDA

More from Agency Leadership